Financings in Brief: Orthofix
This article was originally published in The Gray Sheet
Executive Summary
Orthofix: Announces its intent to expand by 36% its holding in Novamedix, developer of the A-V Impulse System foot-pump for prevention of deep vein thrombosis. Orthofix' acquisition of the additional interest, expected to take place in August, will bring its stake in Novamedix to 80%. The announcement coincides with a decision in the London Patents County Court that NDM(UK) Ltd., marketer of the Act One Foot Pump, had infringed a Novamedix patent and had committed "passing off" by using abstracts of clinical studies in promotional literature for Act One without indicating that the studies related to the A-V Impulse System...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.